 Genotype 1 hepatitis C virus HCV patients who did not respond did not lose virus during treatment or relapsed virus went away on treatment but came back after treatment was stopped after treatment with at least twelve weeks of a pegylated long-acting interferon and ribavirin will be considered for this study. There are two purposes to this study: first, to determine how rosiglitazone, a medicine used to treat diabetes, affects the HCV viral load; and second, to determine if treatment of insulin resistance with rosiglitazone prior to therapy for HCV will improve sustained virologic response loss of virus that continues beyond six months after completion of HCV therapy to HCV therapy. 